News & SEC Filings

View the latest news and SEC filings

News

Ohtuvayre is indicated for the maintenance treatment of COPD allowing for broad use in COPD patients First inhaled COPD treatment providing bronchodilation and non-steroidal anti-inflammatory effects Conference call tomorrow at 8:30 a.m. EDT / 1:30 p.m.

PDUFA Target Action Date for Ensifentrine of June 26, 2024  Finalizing commercial launch preparations Strong balance sheet supports commercialization and pipeline expansion Conference call today at 9:00 a.m. EDT /…

Non-dilutive funding will support planned US commercial launch and expansion of ensifentrine’s clinical activities Cash runway extended beyond 2026 LONDON and RALEIGH, N.C., May 09, 2024 (GLOBE NEWSWIRE) — Verona Pharma…

PDUFA Target Action Date of June 26, 2024 Eight posters including two oral presentations support potential of ensifentrine, an investigational, first-in-class, selective, dual inhibitor of PDE3 and PDE4 LONDON and…

SEC Filings

Date Form Filing Group

April 3, 2017

CORRESP

CORRESP

Other

March 17, 2017

UPLOAD

UPLOAD

Other

PDF

March 3, 2017

mendment to a previously filed DRS

DRS/A

Registration Statements

February 13, 2017

A statement of beneficial ownership of common stock by certain persons

SC 13G

Other

January 30, 2017

mendment to a previously filed DRS

DRS/A

Registration Statements

December 21, 2016

UPLOAD

UPLOAD

Other

PDF

November 23, 2016

Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy

DRS

Registration Statements

July 20, 2016

D

Other

Developing novel therapeutics for respiratory diseases

Verona Pharma (Nasdaq:VRNA) is focused on delivering our strategy and creating value for shareholders.